Paclitaxel Patent Expiration
Paclitaxel is used for treating tumors, breast cancer, lung cancer, and pancreatic cancer. It was first introduced by Hq Specialty Pharma Corp
Paclitaxel Patents
Given below is the list of patents protecting Paclitaxel, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Abraxane |
US9511046 (Pediatric) | Methods of treating pancreatic cancer | Jul 12, 2034 | Bristol-myers |
| Abraxane | US9511046 | Methods of treating pancreatic cancer | Jan 12, 2034 | Bristol-myers |
| Abraxane |
US9393318 (Pediatric) | Methods of treating cancer | Sep 04, 2032 | Bristol-myers |
| Abraxane |
US9597409 (Pediatric) | Methods of treating cancer | Sep 04, 2032 | Bristol-myers |
| Abraxane | US9393318 | Methods of treating cancer | Mar 04, 2032 | Bristol-myers |
| Abraxane | US9597409 | Methods of treating cancer | Mar 04, 2032 | Bristol-myers |
| Abraxane |
US8034375 (Pediatric) | Combinations and modes of administration of therapeutic agents and combination therapy | Feb 13, 2027 | Bristol-myers |
| Abraxane |
US7758891 (Pediatric) | Combinations and modes of administration of therapeutic agents and combination therapy | Aug 21, 2026 | Bristol-myers |
| Abraxane |
US8268348 (Pediatric) | Combinations and modes of administration of therapeutic agents and combination therapy | Aug 21, 2026 | Bristol-myers |
| Abraxane |
US9101543 (Pediatric) | Combinations and modes of administration of therapeutic agents and combination therapy | Aug 21, 2026 | Bristol-myers |
| Abraxane | US8034375 | Combinations and modes of administration of therapeutic agents and combination therapy | Aug 13, 2026 | Bristol-myers |
| Abraxane | US7758891 | Combinations and modes of administration of therapeutic agents and combination therapy | Feb 21, 2026 | Bristol-myers |
| Abraxane | US8268348 | Combinations and modes of administration of therapeutic agents and combination therapy | Feb 21, 2026 | Bristol-myers |
| Abraxane | US9101543 | Combinations and modes of administration of therapeutic agents and combination therapy | Feb 21, 2026 | Bristol-myers |
| Abraxane |
US7820788 (Pediatric) | Compositions and methods of delivery of pharmacological agents |
Apr 27, 2025
(Expired) | Bristol-myers |
| Abraxane | US7820788 | Compositions and methods of delivery of pharmacological agents |
Oct 27, 2024
(Expired) | Bristol-myers |
| Abraxane |
US7923536 (Pediatric) | Compositions and methods of delivery of pharmacological agents |
Jun 09, 2024
(Expired) | Bristol-myers |
| Abraxane |
US8138229 (Pediatric) | Compositions and methods of delivery of pharmacological agents |
Jun 09, 2024
(Expired) | Bristol-myers |
| Abraxane |
US8314156 (Pediatric) | Compositions and methods of delivery of pharmacological agents |
Jun 09, 2024
(Expired) | Bristol-myers |
| Abraxane | US7923536 | Compositions and methods of delivery of pharmacological agents |
Dec 09, 2023
(Expired) | Bristol-myers |
| Abraxane | US8138229 | Compositions and methods of delivery of pharmacological agents |
Dec 09, 2023
(Expired) | Bristol-myers |
| Abraxane | US8314156 | Compositions and methods of delivery of pharmacological agents |
Dec 09, 2023
(Expired) | Bristol-myers |
| Abraxane |
US8853260 (Pediatric) | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
Apr 10, 2021
(Expired) | Bristol-myers |
| Abraxane | US8853260 | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
Oct 10, 2020
(Expired) | Bristol-myers |
| Abraxane | USRE41884 | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
Aug 14, 2016
(Expired) | Bristol-myers |
| Abraxane | US5498421 | Composition useful for in vivo delivery of biologics and methods employing same |
Mar 12, 2013
(Expired) | Bristol-myers |
| Abraxane | US5439686 | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
Feb 22, 2013
(Expired) | Bristol-myers |
| Abraxane | US6096331 | Methods and compositions useful for administration of chemotherapeutic agents |
Feb 22, 2013
(Expired) | Bristol-myers |
| Abraxane | US6506405 | Methods and formulations of cremophor-free taxanes |
Feb 22, 2013
(Expired) | Bristol-myers |
| Abraxane | US6537579 | Compositions and methods for administration of pharmacologically active compounds |
Feb 22, 2013
(Expired) | Bristol-myers |
| Abraxane | US6749868 | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
Feb 22, 2013
(Expired) | Bristol-myers |
| Abraxane | US6753006 | Paclitaxel-containing formulations |
Feb 22, 2013
(Expired) | Bristol-myers |
Paclitaxel's Family Patents
Explore Our Curated Drug Screens
Paclitaxel Generic API Manufacturers
Several generic applications have been filed for Paclitaxel. The first generic version for Paclitaxel was by Teva Pharmaceuticals Usa and was approved on Jan 25, 2002. And the latest generic version is by Cipla Ltd and was approved on Apr 10, 2025.
Given below is the list of companies who have filed for Paclitaxel generic, along with the locations of their manufacturing plants worldwide.
1. ACCORD HLTHCARE
Accord Healthcare Inc has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 6MG/ML | injectable | Prescription | INJECTION | AP | Aug 17, 2018 |
2. ACTAVIS TOTOWA
Actavis Totowa Llc has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Actavis Totowa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 6MG/ML | injectable | Prescription | INJECTION | AP | Dec 9, 2009 |
Manufacturing Plant Locations New
Actavis Totowa's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Actavis Totowa as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
3. ALEMBIC
Alembic Pharmaceuticals Ltd has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Alembic.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 6MG/ML | injectable | Prescription | INJECTION | AP | Oct 20, 2022 |
Manufacturing Plant Locations New
Alembic's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Alembic as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||
4. CIPLA
Cipla Ltd has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Cipla.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG/VIAL | powder | Prescription | INTRAVENOUS | AB | Apr 10, 2025 |
Manufacturing Plant Locations New
Cipla's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Cipla as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||
5. DASH PHARMS
Dash Pharmaceuticals Llc has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Dash Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 6MG/ML | injectable | Discontinued | INJECTION | N/A | Sep 29, 2011 |
6. FRESENIUS KABI USA
Fresenius Kabi Usa Llc has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Fresenius Kabi Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 6MG/ML | injectable | Prescription | INJECTION | AP | Nov 27, 2006 |
Manufacturing Plant Locations New
Fresenius Kabi Usa's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Fresenius Kabi Usa as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
7. GLAND
Gland Pharma Ltd has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Gland.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 6MG/ML | injectable | Prescription | INJECTION | AP | Aug 23, 2016 |
Manufacturing Plant Locations New
Gland's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Gland as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||
8. HENGRUI PHARMA
Jiangsu Hengrui Pharmaceuticals Co Ltd has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Hengrui Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG/VIAL | powder | Prescription | INTRAVENOUS | AB | Oct 8, 2024 |
9. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 6MG/ML | injectable | Prescription | INJECTION | AP | Jan 28, 2002 |
Manufacturing Plant Locations New
Hikma's manufacturing plants are situated in 3 countries - United States, Portugal, Jordan. Given below are the details of these plant locations as well as the firm names of Hikma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||
| Portugal |
| |||||||||
| Jordan |
| |||||||||
10. HOSPIRA
Hospira Inc has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Hospira.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 6MG/ML | injectable | Discontinued | INJECTION | N/A | Aug 1, 2002 |
Manufacturing Plant Locations New
Hospira's manufacturing plants are situated in 3 countries - Australia, United States, Dominican Republic (the). Given below are the details of these plant locations as well as the firm names of Hospira as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Australia |
| |||||||||||||
| United States |
| |||||||||||||
| Dominican Republic (the) |
| |||||||||||||
11. MSN
Msn Laboratories Private Ltd has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Msn.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 6MG/ML | injectable | Prescription | INJECTION | AP | Aug 24, 2020 |
Manufacturing Plant Locations New
Msn's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Msn as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||||||||
| United States |
| |||||||||||||||||||||
12. NORVIUM BIOSCIENCE
Norvium Bioscience Llc has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Norvium Bioscience.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 6MG/ML | injectable | Discontinued | INJECTION | N/A | Jan 25, 2002 |
13. PLIVA LACHEMA
Pliva Lachema As has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Pliva Lachema.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 6MG/ML | injectable | Discontinued | INJECTION | N/A | Mar 12, 2008 |
14. SANDOZ
Sandoz Inc has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Sandoz.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 6MG/ML | injectable | Discontinued | INJECTION | N/A | Dec 26, 2007 |
Manufacturing Plant Locations New
Sandoz's manufacturing plants are situated in 4 countries - Austria, United States, Spain, India. Given below are the details of these plant locations as well as the firm names of Sandoz as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| Austria |
| |||||
| United States |
| |||||
| Spain |
| |||||
| India |
| |||||
15. TEVA PHARMS
Teva Pharmaceuticals Usa has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Teva Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 6MG/ML | injectable | Prescription | INJECTION | AP | Jan 25, 2002 |
16. TEVA PHARMS USA
Teva Pharmaceuticals Usa has filed for 1 generic for Paclitaxel. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 6MG/ML | injectable | Discontinued | INJECTION | N/A | Jan 25, 2002 |